Eruptive xanthomas as a marker for metabolic disorders: A specific form of xanthoma that reflects hypertriglyceridemia

Sohichiroh Ohtaki1 | Kenji Ashida1 | Yuko Matsuo1 | Kanoko Moritaka1 | Shimpei Iwata1 | Ayako Nagayama1 | Aya Kawaguchi2,3 | Hiroshi Koga3 | Satoshi Yoshinobu1 | Nao Hasuzawa1 | Seiichi Motomura1 | Jun Akiba2 | Takekuni Nakama3 | Masatoshi Nomura1

Abstract
Eruptive xanthomas are skin manifestations associated with hypertriglyceridemia. Accordingly, the improvement of hypertriglyceridemia can ameliorate this condition. We report a case of a patient with type 2 diabetes mellitus who was diagnosed with this skin lesion. Clinicians should be aware that eruptive xanthomas could indicate metabolic disorders associated with atherosclerosis.

Keywords
atherosclerosis, diabetes mellitus, eruptive xanthomas, hypertriglyceridemia, insulin action failure

1 |
INTRODUCTION

Early diagnosis and treatment of dyslipidemia are required to prevent the progression of atherosclerosis. Hypertriglyceridemia has been shown to increase the risk of atherosclerosis, which can lead to the development of cardiovascular disease.1 Diabetes mellitus is frequently associated with dyslipidemia, particularly type IIb, III, or IV hyperlipidemias, which can promote hypertriglyceridemia.2,3

Xanthomas are typical skin lesions associated with dyslipidemia that occur as accumulations especially in the Achilles and patellar tendons, extensor tendons of the hands and elbows, eyelids, trunk, and buttocks.4 These skin lesions have been associated with marked hypercholesterolemia, which is typically observed in patients with familial hyperlipidemia type IIa.5

With regard to hypertriglyceridemia, evidence suggests that eruptive xanthomas were associated with serum triglyceride levels.6 Considering the availability
of studies on the clinical courses of eruptive xanthoma,\textsuperscript{7-9} clinicians should familiarize themselves with the details of this condition for correct diagnosis in the early stage.

We herein report on a patient with dyslipidemia complicated with type 2 diabetes mellitus, in whom eruptive xanthoma served as an indicator for hypertriglyceridemia. After the improvement of hypertriglyceridemia through diet and medical treatment, the color tones of the skin lesions had changed from red to white, ultimately disappearing after several months.

2 | CASE HISTORY/EXAMINATION

A 35-year-old Chinese man was admitted to Kurume University Hospital on May 2020 owing to fatigue and hyperglycemia. He stated that hyperlipidemia and hyperglycemia started 2 years prior but that he discontinued any treatment. He had neither any familial history of dyslipidemia and diabetes mellitus nor a life history of drug, alcohol, or smoking abuse. On examination, his body mass index and abdominal circumference were 32 kg/m\textsuperscript{2} and 106.1 cm, respectively. Multiple clustered papules were observed on the bilateral extremities (Figure 1). Histopathological examinations of skin biopsy specimens led to the diagnosis of eruptive xanthomas (Figure 2). Laboratory examinations demonstrated high levels of fasting serum triglyceride (1871 mg/dl) and total cholesterol (371 mg/dl) and low levels of high-density lipoprotein cholesterol (22 mg/dl). However, low-density lipoprotein (LDL) cholesterol levels were within the normal range. Examination of lipoprotein fraction showed that the mid-band and small-dense LDL was contained (Figure 3). Chronic hyperglycemia was also denoted, with a fasting plasma glucose level of 203 mg/dl and HbA1c value (NGSP) of 9.9\% (Table 1). Other examinations, including electrocardiogram and chest radiograph, were unremarkable. Ultrasonography revealed moderate-to-severe fatty liver (Figure 4). Diet therapy with 1600 kcal/day calorie restriction and 0.2 mg/day of pemafibrate, which was ultimately increased to 0.4 mg/day orally, was initiated to reduce serum lipids. Additionally, 500 mg/day of metformin and 10 mg/day of empagliflozin were administered to improve insulin sensitivity and hyperglycemia. Finally, both serum triglyceride and plasma glucose levels improved to 425 and 101 mg/dl, respectively, with a concomitant change in color of the skin lesions from red to white and a decrease in the number of eruptions until total eradication.

3 | DISCUSSION

Eruptive xanthomas develop along with marked hypertriglyceridemia and are an important indicator of metabolic disorders, including dyslipidemia and diabetes mellitus. Grouped papular eruptions 1–4 mm in diameter are specifically observed in the skin over the buttocks, posterior portion of the thigh, elbows, and lumbar region.\textsuperscript{10,11} The accumulation of foaming cells derived from macrophage phagocytosis of remnant lipoprotein is observed on histopathological examination.\textsuperscript{11,12} Hypertriglyceridemia is the highest risk factor for the development of eruptive xanthomas, with 8.5\% of the patients with hypertriglyceridemia above 20 mmol/L (1772 mg/dl) developing this condition and subsequently improving after a reduction in serum triglyceride level.\textsuperscript{8,13} In this context, hypertriglyceridemia and diabetes mellitus have been considered major causative factors for eruptive xanthoma and need to be treated to prevent the progressions of systemic atherosclerosis.\textsuperscript{14} Clinicians should be aware that this type of
skin lesions can indicate the presence of metabolic disorders, which need to be addressed in order to improve the eruptions\(^{11}\) and prevent cardiovascular events.\(^{14}\)

**Figure 2** Histological findings of a skin biopsy specimen from the left forearm. Pathophysiological examination with hematoxylin-eosin staining. (A) Appearance of eruptions. An eruption surrounded by four dotted markings was investigated using microscopy. (B) Low magnitude (×40). Massive foam cells (indicated by arrows) infiltrating into the superficial layer of dermis. (C) High magnitude (×400). Eosinophilic substrate (asterisks), probably indicating extracellular lipids, were observed between collagen fibers. Additionally, foam cells are indicated by arrows.

**Figure 3** Lipoprotein profiles. Lipoprotein fractions are demonstrated using polyacrylamide gel electrophoresis. (A) Results of lipoprotein fraction in wave expression method. (B) Results of polyacrylamide gel staining. Compared to control subjects, high ANGPTL3 activity in patients with hyperglycemia or obesity can induce elevations of serum remnant lipoproteins, chylomicron, or LDL, and VLDL levels.\(^{24}\) Remnants infiltrating into the vessel walls or skin\(^{25}\) are recognized and engulfed by macrophages. After phagocytosis, macrophages change to foam cells and are deposited into the vessel walls and skin,\(^{11}\) which lead to artherosclerosis\(^{26}\) and eruptive xanthoma,\(^{12}\) respectively.
Hypertriglyceridemia should be treated early to prevent progression to acute pancreatitis and cardiovascular events. Severe hypertriglyceridemia over 1000 mg/dl has been found to markedly increase the risk of developing acute pancreatitis. Postprandial hypertriglyceridemia is positively associated with the development of ischemic heart disease, myocardial infarction, and cardiovascular events independent of serum cholesterol levels. In this context, casual hypertriglyceridemia, including postprandial levels as high as fasting levels, have also been indicated to significantly increase the risks of developing cardiovascular events. Additionally, triglyceride-rich lipoprotein and remnant apo-B48-positive chylomicron derived from short intestine are increased during hypertriglyceridemia. Patients with high fasting levels of apo-lipoprotein B48 have been found to be at significant risk for developing coronary artery stenosis. Thus, hypertriglyceridemia requires interventions to prevent the progression of cardiovascular diseases and improve prognosis.

In conclusion, this report details our experience with a patient who presented with hypertriglyceridemia and type 2 diabetes mellitus concurrent with eruptive xanthoma, which was ameliorated by the treatment of dyslipidemia and hyperglycemia. Eruptive xanthoma can help clinicians determine the presence of hypertriglyceridemia and insulin insensitivity induced by obesity and diabetes mellitus, as well as genetic disorders related to lipoprotein metabolism. Clinicians should therefore be aware of skin manifestations of metabolic disorders, which can lead to atherosclerosis.

### TABLE 1 Laboratory data at admission

| Parameters                        | Value | Parameters                        | Value |
|-----------------------------------|-------|-----------------------------------|-------|
| Complete blood cell count         |       | Serum chemistry                   |       |
| Red blood cell count, ×10^12/µl    | 564   | Aspartate aminotransferase, U/L    | 43    |
| Hemoglobin, g/dl                  | 15.1  | Alanine aminotransferase, U/L     | 89    |
| Hematocrit, %                     | 45.7  | γ-glutamyl transferase, U/L       | 63    |
| White blood cell count, /µl       | 5900  | Albumin, g/dl                     | 4.1   |
| Neutrophil, %                     | 57.3  | Creatine kinase, U/L              | 54    |
| Eosinophil, %                     | 2.7   | Triglyceride, mg/dl               | 1871  |
| Lymphocyte, %                     | 35.4  | LDL-C, mg/dl                      | 59    |
| Platelet, ×10^4/µl                | 15.7  | Blood urea nitrogen, mg/dl        | 11    |
| **Endocrinology**                 |       | Creatinine, mg/dl                 | 0.4   |
| Adrenocorticotropic hormone, pg/ml| 41.8  | Sodium, mmol/L                    | 134   |
| Cortisol, µg/dl                   | 8.17  | Potassium, mmol/L                 | 3.6   |
| Dehydroepiandrosterone-sulfate, µg/dl | 153  | Chloride, mmol/L                   | 96    |
| Growth hormone, ng/ml             | <0.03 | Calcium, mg/dl                     | 9.3   |
| Insulin-like growth factor-1, ng/ml| 99    | Phosphate, mg/dl                   | 4.0   |
| Prolactin, ng/ml                  | 14.4  | C-reactive protein, mg/dl         | 1.27  |
| Thyroid-stimulating hormone, µIU/ml| 2.74 | Glucose metabolism                |       |
| Free thyroxine, ng/dl             | 0.95  | Plasma glucose, mg/dl             | 203   |
| Luteinizing hormone, mIU/ml       | 6.0   | HbA1C, % (NGSP)                    | 9.9   |
| Follicular stimulating hormone, mIU/ml | 3.7  | Immunoreactive insulin, µU/ml    | 24.1  |

Abbreviations: HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; NGSP, National Glycohemoglobin Standardization Program.
**ACKNOWLEDGEMENTS**
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors would like to thank Enago (www.enago.jp) for the English language review.

**CONFLICT OF INTEREST**
The authors have no competing interests.

**AUTHOR CONTRIBUTIONS**
SO involved in study design, data collection, drafting, interpretation of data, and revision. KA involved in study design, data collection, drafting, interpretation of the data, review, and revision. YM and KM involved in data collection, interpretation of the data, and review. SI, SM, and AN involved in interpretation of the data and review. AK, JA, and TN involved in data collection, interpretation of the data, and review. MN involved in study design, drafting, interpretation of the data, review, and revision. All authors provided inputs for preparation of the manuscript and have read and approved the final version for submission.

**CONSENT**
All procedures complied with the ethical standards of the Institutional Review Board of the Kurume University School of Medicine and the 2013 Declaration of Helsinki. This report was approved by the Ethics Committee of Kurume University Hospital (2021-067). The patient provided written informed consent for the publication of this study.

**DATA AVAILABILITY STATEMENT**
The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ORCID**
Kenji Ashida https://orcid.org/0000-0001-8753-6016
REFERENCES

1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction withicosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792

2. Arai H, Ishibashi S, Bujo H, et al. Management of type IIb dyslipidemia. J Atheroscler Thromb. 2012;19(2):105-114. doi:10.5551/jat.10447

3. Schaefer JR. Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly. Eur J Hum Genet. 2009;17(5):541-542. doi:10.1038/ejhg.2008.222

4. Maharaj S, Chang S, Nayak SB. Familial hypercholesterolemia presenting with multiple nodules of the hands and elbow. Clin Case Rep. 2015;3(6):411-414. doi:10.1002/ccr3.249

5. Harada-Shiba M, Arai H, Ishigaki Y, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751-770. doi:10.5551/jat.CR003

6. Roga G, Jithendriya M. Eruptive xanthoma: warning sign of systemic disease. Cleve Clin J Med. 2016;83(10):715-716. doi:10.3949/ccjm.83a.15126

7. Solak B, Kara RO, Acikgoz SB, Kosem M. First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep. 2015;2015:bcr201521260. doi:10.1136/bcr-2015-212610

8. Tsuchiya S, Sawada S, Takeda K, et al. Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. Endocr J. 2019;66(1):107-114. doi:10.1507/endocrj.EJ18-0356

9. Kashif M, Kumar H, Khaja M. An unusual presentation of eruptive xanthoma: a case report and literature review. Medicine (Baltimore). 2016;95(37):e4866. doi:10.1097/MD.0000000000004866

10. Abdelghany M, Massoud S. Eruptive xanthoma. Cleve Clin J Med. 2015;82(4):209-210. doi:10.3949/ccjm.82a.14081

11. Zaremba J, Zaczkiewicz A, Placek W. Eruptive xanthomas. Postepy Dermatol Alergol. 2013;30(6):399-402. doi:10.5114/pdia.2013.39439

12. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(2):181-188. doi:10.5507/bp.2014.016

13. Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011;10:157. doi:10.1186/1476-511X-10-157

14. Boullart ACI, de Graaf J, Stalenhoef AF. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta. 2012;1821(5):867-875. doi:10.1016/j.bbapal.2011.10.002

15. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-871. doi:10.1016/j.cell.2012.02.017

16. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185-196. doi:10.1016/j.cmet.2013.01.001

17. Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med. 2013;7(2):207-222. doi:10.1007/s11684-013-0263-5

18. Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity (Silver Spring). 2015;23(3):512-518. doi:10.1002/oby.21003

19. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900-917. doi:10.1016/j.cell.2010.02.034

20. Teo CF, Wollaston-Hayden EE, Wells L. Hexosamine flux, the O-GlcNAC modification, and the development of insulin resistance in adipocytes. Mol Cell Endocrinol. 2010;318(1-2):44-53. doi:10.1016/j.mce.2009.09.022

21. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in ANGPTL3 family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119(1):70-79. doi:10.1172/JCI37118

22. Inukai K, Nakashima Y, Watanabe M, et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004;317(4):1075-1079. doi:10.1016/j.bbrc.2004.03.151

23. Shimamura M, Matsuda M, Kobayashi S, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun. 2003;301(2):604-609. doi:10.1016/s0006-291x(02)03058-9

24. Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. Int J Mol Sci. 2021;22(14):7310. doi:10.3390/ijms22147310

25. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171-183. doi:10.2147/VHRM.S104369

26. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-241. doi:10.1038/35025203

27. Parhofer KG, Laufs U. The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int. 2019;116(49):825-832. doi:10.3238/arztebl.2019.0825

28. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001;153(5):490-499. doi:10.1093/aje/153.5.490

29. Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308-1317. doi:10.1161/CIRCULATIONAHA.119.041998

30. Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24(2):95-109. doi:10.5551/jat.RV16003

31. Alipour A, Valdivielso P, Elite JWF, et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur J Clin Invest. 2012;42(7):702-708. doi:10.1111/j.1365-2362.2011.02635.x

32. Masuda D, Sugimoto T, Tsuji K, et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest. 2012;42(9):992-999. doi:10.1111/j.1365-2362.2012.02687.x

How to cite this article: Ohtaki S, Ashida K, Matsuo Y, et al. Eruptive xanthomas as a marker for metabolic disorders: A specific form of xanthoma that reflects hypertriglyceridemia. Clin Case Rep. 2022;10:e05671. doi:10.1002/ccr3.5671